- Home
- VITL vs CLLS Comparison
VITL vs CLLS Comparison
Compare VITL & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VITL | CLLS |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.1M | 394.4M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VITL | CLLS |
|---|---|---|
| Price | $10.01 | $3.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $32.00 | $8.33 |
| AVG Volume (30 Days) | ★ 3.9M | 27.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $759,444,000.00 | N/A |
| Revenue This Year | $19.72 | N/A |
| Revenue Next Year | $17.02 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $7.95 | $1.33 |
| 52 Week High | $53.13 | $5.48 |
Technical Indicators
Market Signals| Indicator | VITL | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 30.04 |
| Support Level | $7.95 | $2.50 |
| Resistance Level | $10.60 | $3.83 |
| Average True Range (ATR) | 0.62 | 0.18 |
| MACD | 0.23 | -0.07 |
| Stochastic Oscillator | 77.19 | 0.00 |
Price Performance
Historical ComparisonAbout VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.